Early diagnosis and aggressive treatment are essential to mitigate the cascading events that lead to irreversible joint erosion in rheumatoid arthritis.
The use of gold therapy as an anticancer agent appears promising, as does its more common use as a DMARD.
Glucocorticoid therapy in patients with rheumatoid arthritis has been linked to elevated risk of diabetes.
After 8 weeks, patients with rheumatoid arthritis who took probiotics showed improvements in disease activity and metabolic health.
Nearly 12% of patients in remission from RA still experience clinically significant pain.
The biosimilar has also been approved for Crohn's disease, ulcerative colitis, and ankylosing spondylitis.
In patients with rheumatoid arthritis, there are disparities between radiologic and goniometric measurements of joint deviation.
A molecule found in green tea may block a protein that causes the symptoms of rheumatoid arthritis.
RA patients treated with biologics have exhibited either clinical remission or low disease activity on follow-up visits.
Cardiovascular deaths have significantly decreased among people with rheumatoid arthritis.
Due to improved treatment options, rheumatoid arthritis mortality rates have decreased since 2000.
Updated American College of Rheumatology recommendations suggest using first-line DMARDs in combination with biologic agents and nonbiologic DMARDs to achieve therapeutic efficacy in rheumatoid arthritis treatment.
Research has shown a positive correlation between bariatric surgery-associated weight loss and decreased rheumatoid arthritis disease activity.